Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 247 clinical trials
A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies

This is a Phase I, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of a novel BTK inhibitor, ICP-022. During this study, dose escalation will be conducted in patients diagnosed with refractory/relapsed (r/r) B-cell malignancies including only patients with Grades1-3a follicular lymphoma (FL); marginal zone lymphoma (MZL); …

renal function tests
lymphocytic leukemia
bone marrow infiltration
ct scan
leukemia
  • 7 views
  • 28 Jan, 2021
  • 8 locations
Study of TG-1701 an Irreversible Bruton's Tyrosine Kinase Inhibitor in Patients With B-Cell Malignancies

This is a Phase 1 trial to evaluate the safety, pharmacokinetics and efficacy of TG-1701, a Bruton's Tyrosine Kinase (BTK) inhibitor in patients with relapsed or refractory B-cell malignancies

cancer
lymphoma
b-cell lymphoma
tyrosine
  • 117 views
  • 16 Apr, 2021
  • 15 locations
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

This phase II trial studies how well ABL001 works in treating patients with chronic myeloid leukemia who are on therapy with tyrosine kinase inhibitor. ABL001 may stop the growth of cancer cells

  • 0 views
  • 26 Jan, 2021
A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia

This trial studies the feasibility and acceptability of a mobile intervention called txt4TKI for the improvement of tyrosine kinase inhibitor management in patients with chronic myeloid leukemia

  • 0 views
  • 27 Jan, 2021
  • 1 location
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in participants with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrm macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma intolerant of prior ibrutinib and/or acalabrutinib treatment, compared with their ibrutinib and/or acalabrutinib intolerance …

lymphocytic leukemia
ibrutinib
chronic lymphocytic leukemia
acalabrutinib
platelet count
  • 16 views
  • 27 Jan, 2021
  • 30 locations
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor

body (metastatic) and that are being treated with vascular endothelial growth factor-tyrosine kinase inhibitor therapy. Studying samples of blood and stool from patients who eat probiotic yogurt and

kinase inhibitor
vascular endothelial growth factor
vegf
kidney cancer
cancer
  • 20 views
  • 27 Jan, 2021
  • 1 location
Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.

The purpose of this study is to evaluate the efficacy and safety of fruquitinib or regorafenib in combination with anti-PD-1 antibody in TKI (fruquitinib or regorafenib)-responded MSS/pMMR metastatic colorectal adenocarcinoma.

  • 0 views
  • 25 Jan, 2021
  • 1 location
Randomized Trial of Topotecan With M6620 an ATR Kinase Inhibitor in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

This phase II trial studies how well M6620 works when given in combination with topotecan hydrochloride (topotecan) compared with topotecan alone in treating patients with small cell lung cancer that has come back (relapsed), or small cell cancer that arises from a site other than the lung (extrapulmonary). Drugs used …

therapeutic agents
topotecan
hepatitis b
cancer
ATR
  • 4 views
  • 02 Apr, 2021
  • 12 locations
Phase II Trial of AZD6738 Alone and in Combination With Olaparib

This phase II trial studies how well ATR kinase inhibitor AZD6738 works alone or in combination with olaparib in treating participants with renal cell carcinoma, urothelial carcinoma, all

metastatic disease
solid tumor
tumor cells
baf250a
direct bilirubin
  • 23 views
  • 16 Apr, 2021
  • 1 location
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

: NCT01883219) demonstrated that pre-emptive tyrosine kinase inhibitor (TKIs) administration based on minimal residual disease (MRD) and BCR-ABL mutation after allo-HSCT might reduce the incidence of relapses

philadelphia chromosome-positive acute lymphoblastic leukemia
stem cell transplantation
philadelphia chromosome
remission
leukemia
  • 14 views
  • 22 Jan, 2021
  • 1 location